Related Experiment Video

Updated: Mar 2, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma

Matias A Bustos1, Shigeshi Ono1, Diego M Marzese1

  • 1Department of Translational Molecular Medicine, Division of Molecular Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA.

The Journal of Investigative Dermatology
|May 21, 2017
PubMed

Insights

MicroRNA-200a acts as a cell cycle brake in melanoma by targeting CDK6. Its loss promotes metastasis and influences response to CDK4/6 inhibitors in advanced melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The CDK4/6 pathway is frequently dysregulated in cutaneous melanoma.
  • CDK4/6 inhibitors show clinical promise in various cancers, including melanoma.

Purpose of the Study:

  • To investigate the role of microRNA-200a in melanoma progression and its impact on CDK4/6 inhibitor response.
  • To elucidate the mechanism by which microRNA-200a regulates cell proliferation and metastasis.

Main Methods:

  • Analysis of microRNA-200a expression in melanoma cells and its association with disease progression.
  • Investigating the epigenetic regulation of microRNA-200a.
  • Functional studies involving microRNA-200a and CDK6 overexpression/knockdown in melanoma cell lines.
  • Assessment of cell cycle, proliferation, and response to CDK4/6 inhibitors.

Main Results:

  • MicroRNA-200a down-regulation correlates with melanoma progression and increased lymph node metastasis.
  • MicroRNA-200a directly targets and decreases CDK6 expression, leading to cell cycle arrest.
  • Epigenetic mechanisms, including DNA methylation and chromatin accessibility, modulate microRNA-200a expression.
  • Low microRNA-200a expression in metastatic melanoma enhances sensitivity to CDK4/6 inhibitors.

Conclusions:

  • MicroRNA-200a functions as a tumor suppressor and a cell cycle brake in melanoma.
  • Loss of microRNA-200a during melanoma progression contributes to metastasis.
  • MicroRNA-200a levels can predict melanoma proliferation and response to CDK4/6 inhibitors.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.6K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K